Infections of the Esophagus, Stomach, and Duodenum

INFECTIONS OF THE ESOPHAGUS, STOMACH, AND DUODENUM

OVERVIEW

This section of the handout will discuss infectious diseases of the esophagus (esophagitis), the stomach (gastritis and gastric ulcers), and the upper duodenum (duodenal ulcers). A general term used when referring to ulcers of the stomach and duodenum is peptic ulcer disease. Esophagitis usually occurs in immunocompromised persons.

Esophagitis

Infectious esophagitis is an infection and inflammation of the esophagus that results in dysphagia and odynophagia.

Etiology

Table 1. Unique Manifestations of Esophagitis by Causative Agent

Causative Agent

Unique manifestation

Candida albicans

Patients usually also have acute pseudomembranous candidiasis

Herpes simplex virus (HSV)

Abrupt onset of symptoms

Earliest esophageal lesions are 1- to 3-mm round vesicles in the middle to distal esophagus

Multinuclear giant cells are present (identified by Tzanck test in biopsy material)

Cytomegalovirus (CMV)

Gradual onset of symptoms

No cases of CMV esophagitis have been reported in hosts with normal immune function

Large solitary, shallow ulcers or multiple discrete lesions at the distal end of the esophagus are often present

Human immuno-deficiency virus (HIV)

Early lesions are small and aphthoid (thrush-like) and occur during a period of transient fever, chills, malaise, and the rash seen in early HIV infection

Later, giant deep ulcers as large as several centimeters in diameter can be seen

Fistula formation, perforation, hemorrhage, or superinfection may complicate large ulcers

Varicella zoster virus

Patients usually have dermatologic lesions consistent with chickenpox or shingles

Many different microorganisms can cause infectious esophagitis; however, the most common infectious cause of esophagitis is Candida albicans. Other important causes include cytomegalovirus (CMV), herpes simplex virus (HSV), varicella zoster virus (VZV), and human immunodeficiency virus (HIV).

Manifestations

A patient with esophagitis has acute onset of dysphagia (difficulty swallowing), odynophagia (painful swallowing), heartburn retrosternal discomfort or pain, nausea and vomiting, fever, abdominal pain, epigastric pain, anorexia, weight loss, and cough. See Table 1 for unique manifestations of infectious esophagitis listed by causative agent.

Epidemiology

Esophagitis is most common in immunocompromised patients. Symptomatic infection is increased in patients with AIDS, leukemia, and lymphoma but uncommon in the general population.
C albicans esophagitis is an AIDS-defining condition in an HIV-infected patient.
Approximately 8–28% of AIDS patients with dysphagia and odynophagia have been found to have cultures positive for CMV.
Major predisposing factors of esophagitis include antibiotic use, radiation therapy or chemotherapy, hematologic malignancies, and AIDS.

Pathogenesis

Infectious esophagitis usually occurs in immunosuppressed persons. A wide range of abnormalities in host defense may predispose an individual to this opportunistic infection, such as neutropenia, impaired chemotaxis, phagocytosis, alteration in humoral immunity, and impaired T-cell lymphocyte function. Corticosteroids, cytotoxic agents, radiation, and immune modulators may also contribute to impaired host immune function. Disruption of mucosal protective barriers and antibiotics that suppress the normal bacterial flora can also contribute to invasion of the esophagus by organisms in the normal flora.

Patients with HIV and persistently low CD4 counts are more likely to develop fungal esophagitis. Illnesses that interfere with esophageal peristalsis such as achalasia, progressive systemic sclerosis, and esophageal neoplasias can increase the likelihood of developing fungal esophagitis. Patients with systemic diseases, such as diabetes mellitus, adrenal dysfunction, and alcoholism, and the elderly are also more likely to develop infectious esophagitis.

Diagnosis

Odynophagia, painful swallowing, is a symptom that is unique to infectious esophagitis. If a patient with dysphagia (difficulty in swallowing) also mentions odynophagia, esophagogastroduodenoscopy (EGD) is the preferred procedure to confirm the diagnosis because it allows direct visualization and sampling of the mucosal tissue.

Treatment and Prevention

Infectious esophagitis due to C albicans can be treated with clotrimazole. Patients with infectious esophagitis due to HSV or CMV can be treated with ganciclovir. Corticosteroids can be given to reduce the inflammatory response. Patients should avoid situations that cause immunosuppression or destroy the composition of the normal flora (e.g., broad-spectrum antibiotic therapy).

Infections of the Stomach and Upper Duodenum

Chronic active gastritis, gastric ulcer disease, and duodenal ulcer disease are inflammatory diseases that are usually caused by Helicobacter pylori. Chronic active gastritis is an inflammation or irritation of the stomach lining; gastric ulcer disease develops in the stomach; and duodenal ulcer disease is chronic and recurrent and results in deep and sharply demarcated ulcers within the first 3 cm of the duodenum. The more general term used is peptic ulcer disease (PUD), which includes both gastric and duodenal ulcer disease.

Etiology

The most common cause of infectious chronic active gastritis and PUD is H pylori, a short, spiral-shaped, microaerophilic gram-negative bacillus. Most cases of gastric carcinoma are the consequence of lifelong H pylori infection and the effect that this chronic infection has on mucosal carcinogenesis.

Manifestations

Chronic active gastritis is usually asymptomatic; however, when symptoms do exist, they include pain or discomfort, with the pain usually located in the upper central portion of the abdomen (the “pit” of the stomach) (Table 2). Symptoms can occur suddenly, which is particularly true in persons older than 65 years of age.

Table 2. Manifestations of Gastritis and Peptic Ulcer Disease (PUD)
Disease	Manifestations
Chronic active gastritis	Pain usually located in the upper central portion of the abdomen or the “pit” of the stomach, may feel like it is “going right straight through” as it travels from the belly to the back Pain is a burning, aching, gnawing, or sore Urge to belch, but belching either does not relieve the pain or relieves it only briefly Nausea and vomiting (vomitus may be clear, green, or yellow and blood-streaked or completely bloody)
Critically ill patient with chronic active gastritis	All the symptoms listed above for chronic active gastritis and in addition patients may: Become pale and sweaty, and have tachycardia Vomit blood, have bloody stools or dark sticky, foul-smelling stools
PUD (includes gastric and duodenal ulcers)	Gnawing or burning pain in the epigastrium Bleeding that may result in anemia, weakness, and fatigue Hematemesis, hematochezia, or melena
Unique characteristics of gastric and duodenal ulcerative disease
Gastric ulcer		Pain is made worse by eating
Duodenal ulcer		Pain is usually relieved by eating or by antacids

The most common symptom of PUD is gnawing or burning pain in the epigastrium, which typically occurs when the stomach is empty (90 minutes to 3 hours after a meal), between meals, and in the early morning hours (see Table ESU-2). The duration of pain may be minutes to hours. Symptoms of PUD may last for weeks to months with remissions that may last months to years followed by recurrence of the symptoms.

Epidemiology

Approximately 50% of the world’s population is infected with H pylori; prevalence of H pylori infection in the U.S. is about 35–40%.
In the U.S., H pylori is most prevalent among adults older than 60 years of age and in African Americans, Hispanics, and lower socioeconomic groups.

Chronic active gastritis

About 20% of individuals infected with H pylori develop chronic active gastritis.
The male to female ratio of chronic active gastritis is 1:1.

Peptic ulcer disease

Over 25 million Americans will suffer from PUD during their lifetime. Each year, there are 500,000 to 850,000 new cases of PUD and more than one million ulcer-related hospitalizations.
Most cases of PUD are caused by H pylori, NOT by spicy food, acid, or stress.
The primary factor predisposing people to PUD is colonization with H pylori; genetic factors also may be important predisposing factors for PUD. About 50% of children with duodenal ulcer disease have a first- or second-degree relative with duodenal ulcer disease.
Persons with blood group O have a higher incidence of duodenal ulcer disease.
Duodenal ulcerative disease usually occurs in persons 25–75 years of age.
Gastric ulcerative disease usually occurs in persons 55–65 years of age.
The male to female ratio for gastric and duodenal ulcer disease is 2:1.
There is an association between long-term infection with H pylori and the development of gastric adenocarcinomas or lymphomas.
Transmission of H pylori is person to person, and humans are the only known reservoir.

Pathogenesis

Infection with H pylori is associated with virtually all ulcers not induced by nonsteroidal antiinflammatory drugs (NSAIDs). H pylori cells colonize the deep layers of the mucosal gel that coats the gastric mucosa and disrupts its protective properties. The bacterium is motile and uses its “corkscrew”-like motility to migrate within the gastric and duodenal mucosa.

Researchers do not understand completely the pathogenesis of H pylori bacteria and the formation of ulcers. However, the ability of the bacteria to sense pH, produce flagella, urease, cytotoxic protein called vac A (vacuolating toxin), and the cagA gene product are important in the pathogenesis of ulcer formation. The bacteria produce large amounts of urease allowing them to generate ammonium ions, which buffer the gastric acid. The vac A protein causes vacuoles to form in certain cells and has been demonstrated to cause pore formation in human cells. The cagA gene product is injected in host cells by the bacteria, which causes several changes in host cell signaling.

Colonization of H pylori in the stomach and duodenum is associated with an accumulation of inflammatory cells in the lamina propria. The inflammatory cells release cytokines (e.g., tumor necrosis factor alpha, IL-1, and IL-8) that reduce somatostatin levels and cause an increase in gastrin levels. Damage to tissues results in gastritis and eventually causes an ulcer. The ulcers are usually less than 1 cm in diameter and penetrate through the mucosa and submucosa and into the muscularis propria. The ulcer floor has no intact epithelium; it normally contains a zone of eosinophilic necrosis resting on a base of granulation tissue surrounded by variable amounts of fibrosis. Researchers believe that H pylori infects virtually all patients who are diagnosed with chronic active gastritis.

Long term inflammation of the stomach is believed to result in gastric carcinoma. Some have show that chronic increase in TNF-alpha production is an important instigator of cancer formation in the stomach. An extracellular protein produced by H pylori called TNF-alpha inducing protein (Tip-alpha) is believed to through other cytokines initiate carcinogenesis over time. Tip-alpha is endocytosed by the gastric epithelial cells and through NF-kappaB produces increased amounts of TNF-alpha. Isolates of H pylori from patients with gastric carcinoma produce much more Tip-alpha that H pylori from patients without gastric cancer.

Diagnosis

Diagnosis of gastritis and PUD involves recognizing the common signs and symptoms and determining that H pylori infection is present; this can be determined with a serologic test, a C13 radiolabeled urea breath test, and by endoscopy with tissue biopsy. Endoscopy allows direct visualization of gastritis, ulcers, and carcinomas. Biopsy specimens can be tested for H pylori urease activity and examined for inflammation and abnormal tissue.

Treatment and Prevention

Treatment of chronic gastritis and PUD involves three or four drugs; Triple drug regimen= a proton pump inhibitor (i.e., lansoprazole or omeprazole) and two antibiotics (i.e., amoxicillin and clarithromycin); Quadruple drug regimen= proton pump inhibitor (i.e., lansoprazole or omeprazole), bismuth (Pepto-Bismol), and two antibiotics (i.e., tetracycline and metronidazole). Unfortunately, treatment failures occur in about 27% of the patients that follow either of the treatment regimens mentioned above. There is no difference in treatment failures between the triple or quadruple drug treatment regimens.

No prevention methods or vaccines have been discovered thus far for H pylori infection in humans. Treatment of patients with chronic gastritis and PUD lowered by 40% the number of patients who developed gastric carcinoma in a recent study in Japan. Unfortunately, the findings were not statistically significant for a number of reasons. Further studies are pending.

Return to Syllabus